|1.||Lavranos, Tina C: 3 articles (01/2014 - 06/2010)|
|2.||Leske, Annabell F: 3 articles (01/2014 - 06/2010)|
|3.||Kremmidiotis, Gabriel: 3 articles (01/2014 - 06/2010)|
|4.||Hall, Allison J: 1 article (01/2014)|
|5.||Beaumont, Donna M: 1 article (01/2014)|
|6.||Inglis, Daniel J: 1 article (01/2014)|
|7.||Brown, Chloe K: 1 article (01/2014)|
|8.||Paul, Dharam: 1 article (09/2011)|
|9.||Chalmers, David K: 1 article (09/2011)|
|10.||Morizzi, Julia: 1 article (09/2011)|
06/01/2010 - "Tissue distribution analysis of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 hours after administration, it is still present at high concentrations within the solid tumor mass. "
01/01/2014 - "We combined these agents with BNC105 to explore the effects on tumor vasculature, tumor growth inhibition and animal survival. "
01/01/2014 - "We sought to identify the molecular and cellular events activated following BNC105 treatment that drives tumor recovery. "
06/01/2010 - "Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals."
01/01/2014 - "Combination treatment of BNC105 with everolimus also increased tumor growth inhibition. "
|2.||Breast Neoplasms (Breast Cancer)
|3.||Kidney Neoplasms (Kidney Cancer)
01/01/2014 - "BNC105 is currently being evaluated in a randomized phase II clinical trial in combination with everolimus in renal cancer. "
01/01/2014 - "Consistent with this, addition of BNC105 to pazopanib treatment resulted in a significant increase in survival in an orthotopic renal cancer model. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)